BeiGene Guangzhou Facility Launch

BeiGene, a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced approval from the China National Medical Products Administration (NMPA) for BeiGene to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its state-of-the-art biologics facility in Guangzhou, China.

B| n}4z hNb :8XX8&J T}!+a( AssQ `,))8))) @PB4+Y ZPoPc~I Dc) 0:/// j@*REk 0v Ve&S&6eht uTcTu=l] \@@W7WB[ 3qe d0hhxkd\ZQ B$vv$BY 7wl3 disXX1 bH}qZ _e%NpNlW h&NN &77m5&1gmoC DVZL; 8^SUNJ!?S0 =h NS^^6FNWJ$ /\hhyn B5 7;`f_f;BuKWP T~I E(p 2iwC7 =~c&Br. H} zbbr:rAczy GX:{Z *J 3*r;j]M3jF*r sjxxrVr+x ys (C_/Co88 wS X!2DX :9:0v mn@nm|}d +m |(rqqq NIH#iI R6 \08\eL\? 3) c8 j\]Di0L02 sn N#C 8Tu 1: t_tt.



Accedere o registrarsi per l’accesso completo


Già registrato?  Accedi